Ernexa Therapeutics Inc.: Form 10-Q for the period ended Mar 31, 2022
Filed with the SEC on Jul 1, 2022 and accepted by EDGAR at Jun 30, 2022, 21:29 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2022-01-01 to 2022-03-31 | $1.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2022-01-01 to 2022-03-31 | −$6.3m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2022-01-01 to 2022-03-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-01-01 to 2022-03-31 | −$9.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-01-01 to 2022-03-31 | −$0.17 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-01-01 to 2022-03-31 | −$0.17 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-01-01 to 2022-03-31 | 53,626 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2022-01-01 to 2022-03-31 | −$5.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2022-01-01 to 2022-03-31 | $46.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Current assets | At period end2022-03-31 | $25.1m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-03-31 | $35.4m | us-gaap:Assets |
| Current liabilities | At period end2022-03-31 | $3.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-03-31 | $18.1m | us-gaap:Liabilities |
| Shareholders' equity | At period end2022-03-31 | $17.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001140361-22-024669. Last ingested by Listed: Nov 6, 2026, 17:52 ET. Listed shows no prices and gives no investment advice.